Zalutumumab Biosimilar - Research Grade

Human

EGFR

>1mg/ml

Human IgG1 Kappa

Bulk Anti-Human EGFR (EGFR.1) Antibody (ICH1021), Cetuximab Biosimilar - Research Grade (ICH4004), Matuzumab Biosimilar - Research Grade (ICH4007), Nimotuzumab Biosimilar - Research Grade (ICH4008), Panitumumab Biosimilar - Research Grade (ICH4028), Necitumumab Biosimilar - Research Grade (ICH5121), Depatuxizumab Biosimilar - Research Grade (ICH5294), Becotatug Biosimilar - Research Grade (ICH5378), Demupitamab Biosimilar - Research Grade (ICH5473), Futuximab Biosimilar - Research Grade (ICH5560), Imgatuzumab Biosimilar - Research Grade (ICH5600), Laprituximab Biosimilar - Research Grade (ICH5626), Losatuxizumab Biosimilar - Research Grade (ICH5657), Modotuximab Biosimilar - Research Grade (ICH5691), Pimurutamab Biosimilar - Research Grade (ICH5774), Serclutamab Biosimilar - Research Grade (ICH5853), Tomuzotuximab Biosimilar - Research Grade (ICH5933)

https://www.imgt.org/mAb-DB/

ICH3002

P00533

Blue ice

This is a research-grade, unconjugated recombinant analog of zalutumumab, a fully human IgG1 kappa antibody directed against the epidermal growth factor receptor (EGFR/HER1). It is supplied strictly for research use only and is not the clinical therapeutic; it is not intended for human or veterinary use. The molecule reproduces the antigen-binding specificity of the originator against human EGFR, making it a convenient tool for studying receptor engagement, ligand-competition, and downstream signaling in cell-based systems. Because it is built on a human IgG1 backbone, it is useful for interrogating Fc-mediated effector functions such as antibody-dependent cellular cytotoxicity (ADCC) in vitro. Typical applications include positive and reference controls in EGFR binding and neutralisation assays, benchmarking of biosimilar or novel anti-EGFR candidates, flow cytometry and immunoassay standardisation, and as a building block for antibody-drug-conjugate (ADC) or engineering workflows. It is offered as low-endotoxin, bulk-scale material (research grade typically <1 EU/mg, with ultra-low <0.5 EU/mg options), supporting reproducible in-vitro and preclinical experimentation at milligram-to-gram scale. EGFR (encoded by EGFR, UniProt P00533; also called HER1/ErbB1) is a single-pass transmembrane receptor tyrosine kinase and a founding member of the ErbB family. Ligands such as EGF, TGF-alpha, amphiregulin, and epiregulin bind the extracellular domain, driving receptor homo- or heterodimerisation with other ErbB members (HER2, HER3, HER4). Dimerisation activates the intracellular kinase domain, triggering autophosphorylation and recruitment of adaptors that fire the RAS-RAF-MAPK, PI3K-AKT, and JAK-STAT pathways, which govern proliferation, survival, migration, and differentiation. EGFR is overexpressed, amplified, or mutated in many epithelial cancers, including head-and-neck squamous cell carcinoma, colorectal, and non-small-cell lung cancer, making it a validated oncology target. Zalutumumab binds the receptor ectodomain to block ligand-induced activation and can additionally engage Fc-dependent effector mechanisms.

Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, Epidermal growth factor receptor, ERBB, ERBB1, HER1

Detects human EGFR

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.